SCHEMBL2170717

SCHEMBL2170717

COC(=O)C(C)c1ccc(NC(N)=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.60
GLA P06280 1/20 0.56
PEPD P12955 1/20 0.48
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 1/20 0.47
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RAB9A P51151 1/20 0.45
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
GFER P55789 1/20 0.44
LMNA P02545 1/20 0.43
MT-CO2 P00403 1/20 0.42
MAPK1 P28482 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261230 1.00 KIF11 (0.60) KIF11GLAPEPDALDH1A1NPC1
SCHEMBL2172524 1.00 KIF11 (0.60) KIF11GLAPEPDALDH1A1NPC1
SCHEMBL2170844 0.87 ALDH1A1 (0.47) KIF11GLAALDH1A1HPGDMEN1
SCHEMBL2171946 0.87 ALDH1A1 (0.47) KIF11GLAALDH1A1HPGDMEN1
SCHEMBL262073 0.87 ALDH1A1 (0.47) KIF11GLAALDH1A1HPGDMEN1
SCHEMBL1447652 0.84 SMN1; SMN2 (0.56) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL2818448 0.82 KIF11 (0.64) KIF11GLAPEPDALDH1A1NPC1
SCHEMBL2172516 0.82 KIF11 (0.64) KIF11GLAPEPDALDH1A1NPC1
SCHEMBL11272564 0.80 HPGD (0.49) ALDH1A1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL5533028 0.80 KIF11 (0.89) KIF11GLAPEPDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346841-B1 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ S P A (IT) 2015-01-14 EP claimed
US-20110207785-A1 2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them DOMPE S.P.A. (IT) 2011-08-25 US claimed
EP-2346841-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe S.p.A. (IT) 2011-07-27 EP claimed
WO-2010031835-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2010-03-25 WO claimed
EP-2166006-A1 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them Dompe' S.P.A. (IT) 2010-03-24 EP claimed
EP-2346841-B1 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ S P A (IT) 2015-01-14 EP disclosed
CN-102159558-B 2-arylpropionic acids and derivatives thereof and pharmaceutical compositions containing said compounds DOMPE SPA 2015-01-07 CN disclosed
US-8624036-B2 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them DOMPE S.P.A. (IT) 2014-01-07 US disclosed
US-20110207785-A1 2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them DOMPE S.P.A. (IT) 2011-08-25 US disclosed
CN-102159558-A 2-arylpropionic acids and derivatives thereof and pharmaceutical compositions containing said compounds DOMPE SPA 2011-08-17 CN disclosed
EP-2346841-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe S.p.A. (IT) 2011-07-27 EP disclosed
WO-2010031835-A2 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2010-03-25 WO disclosed
EP-2166006-A1 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them Dompe' S.P.A. (IT) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207785-A1 2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them CXCR3, F2RL1, FPR2 KIF11 3523/4885GLA 1923/4885PEPD 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.